Ligand Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Ligand Pharmaceuticals CEO'su Todd Davis, Dec2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 6.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.5% maaş ve 89.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.43% ine doğrudan sahiptir ve bu hisseler $ 10.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 15 yıldır.
Anahtar bilgiler
Todd Davis
İcra Kurulu Başkanı
US$6.2m
Toplam tazminat
CEO maaş yüzdesi | 10.5% |
CEO görev süresi | 1.9yrs |
CEO sahipliği | 0.4% |
Yönetim ortalama görev süresi | 2yrs |
Yönetim Kurulu ortalama görev süresi | 15yrs |
Son yönetim güncellemeleri
Recent updates
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$45m |
Jun 30 2024 | n/a | n/a | US$42m |
Mar 31 2024 | n/a | n/a | US$96m |
Dec 31 2023 | US$6m | US$650k | US$54m |
Sep 30 2023 | n/a | n/a | US$21m |
Jun 30 2023 | n/a | n/a | US$41m |
Mar 31 2023 | n/a | n/a | US$51m |
Dec 31 2022 | US$6m | US$49k | -US$5m |
Sep 30 2022 | n/a | n/a | US$23m |
Jun 30 2022 | n/a | n/a | US$27m |
Mar 31 2022 | n/a | n/a | US$45m |
Dec 31 2021 | US$328k | n/a | US$76m |
Sep 30 2021 | n/a | n/a | US$68m |
Jun 30 2021 | n/a | n/a | US$48m |
Mar 31 2021 | n/a | n/a | US$39m |
Dec 31 2020 | US$329k | n/a | US$7m |
Sep 30 2020 | n/a | n/a | -US$16m |
Jun 30 2020 | n/a | n/a | -US$25m |
Mar 31 2020 | n/a | n/a | -US$61m |
Dec 31 2019 | US$350k | n/a | US$629m |
Sep 30 2019 | n/a | n/a | US$594m |
Jun 30 2019 | n/a | n/a | US$677m |
Mar 31 2019 | n/a | n/a | US$764m |
Dec 31 2018 | US$343k | n/a | US$143m |
Sep 30 2018 | n/a | n/a | US$179m |
Jun 30 2018 | n/a | n/a | US$120m |
Mar 31 2018 | n/a | n/a | US$53m |
Dec 31 2017 | US$283k | n/a | US$13m |
Tazminat ve Piyasa: Todd 'ın toplam tazminatı ($USD 6.22M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.54M ).
Tazminat ve Kazançlar: Todd 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Todd Davis (63 yo)
1.9yrs
Görev süresi
US$6,216,518
Tazminat
Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Chromocell Therapeutics Corporation since January 2023 and its Chairman of the Board. He is Chief Exec...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 1.9yrs | US$6.22m | 0.43% $ 10.3m | |
Chief Financial Officer | 2yrs | US$2.45m | 0.13% $ 3.2m | |
Chief Legal Officer & Secretary | 2yrs | US$2.34m | 0.12% $ 2.9m | |
Senior Vice President of Investments & Business Development | no data | Veri yok | Veri yok | |
Head of Investor Relations | no data | Veri yok | Veri yok | |
Director of Corporate Development | no data | Veri yok | Veri yok | |
Senior Vice President of Biology & Scientific Affairs | 6.8yrs | Veri yok | Veri yok | |
Senior Vice President of Technical Operations & QA - Capitsol | 6.8yrs | Veri yok | Veri yok | |
Senior VP & CBO Protein Expression Business | no data | Veri yok | Veri yok | |
Senior VP of Investments & Head of Clinical Strategy | less than a year | Veri yok | Veri yok | |
Senior VP of Investment Operation | less than a year | Veri yok | Veri yok | |
CEO of Pelthos Therapeutics | less than a year | Veri yok | Veri yok |
2.0yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: LGND 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 17.7yrs | US$6.22m | 0.43% $ 10.3m | |
Independent Chairman | 21.7yrs | US$361.70k | 0.23% $ 5.5m | |
Independent Director | 13.8yrs | US$329.20k | 0.15% $ 3.7m | |
Independent Director | 16.3yrs | US$341.70k | 0.16% $ 3.8m | |
Independent Director | 18.2yrs | US$339.20k | 0.45% $ 10.6m | |
Scientific Advisor | no data | Veri yok | Veri yok | |
Independent Director | 2.4yrs | US$346.70k | 0.023% $ 538.5k | |
Independent Director | 7.3yrs | US$336.70k | 0.031% $ 731.6k | |
Independent Director | 1.2yrs | US$467.87k | Veri yok |
15.0yrs
Ortalama Görev Süresi
63.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: LGND 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15 yıldır).